Skip to main content
Caplight Logo









Adoram Therapeutics

Adoram Therapeutics

Private
SwitzerlandHealthcare & Life Scienceshttps://adoram.ch/

Last Round

Grant

May 5, 2025

Total Funding Raised

$1.3M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Adoram Therapeutics is a biotechnology company that develops allosteric modulators for the treatment of solid tumors and immune-based diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Infrastructure

Keywords

allosteric modulationG protein-coupled receptorsGPCRsmall molecule therapydrug discovery platformAI drug discoveryadenosine 2A receptorA2ARsolid tumor immunotherapyNAMnegative allosteric modulatorpositive allosteric modulatorPAMin silico drug designbiotech partnershipcomputational biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Adoram Therapeutics Comparables

Compare Adoram Therapeutics with similar companies based on industry and business-model similarity.

Adoram Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
KyDo Therapeutics
80%
Palobiofarma S.L.
80%
Nxera Pharma
78%

Adoram Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 5, 2025
Pre SeedFeb 25, 2025
SeedOct 24, 2024
AcceleratorFeb 23, 2024
GrantApr 11, 2023

Key People

Founding team and executive leadership

Hesham Ismail HAMED

Co-CEO, Chief Scientific Officer (CSO), Co-Founder And Board Member

Founding Team

Adoram Therapeutics Investors

Notable investors and investment history

Adoram Therapeutics investors
InvestorRounds
FongitSeed, Pre Seed
InnosuisseGrant
Venture KickAccelerator, Grant
InnosuisseGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors increased 48% MoM.

  • May 17, 2026

    Monthly visitors increased 82% MoM.

Adoram Therapeutics Filings

Explore SEC and related filing metadata, where available.

Adoram Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Adoram Therapeutics's valuation, stock price, and market status.

Is Adoram Therapeutics a public or private company?

Adoram Therapeutics is a private company.

What is the current stock price of Adoram Therapeutics?

Adoram Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Adoram Therapeutics worth (valuation)?

Valuation information for Adoram Therapeutics is not publicly available.

Can I buy Adoram Therapeutics stock?

Adoram Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Adoram Therapeutics's last funding round?

Adoram Therapeutics's most recent funding round was Grant on May 15, 2025.

Who are the main investors in Adoram Therapeutics?

Key investors in Adoram Therapeutics include Innosuisse.

Will Adoram Therapeutics IPO soon?

No public IPO plans have been announced for Adoram Therapeutics.

How can I track Adoram Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Adoram Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSwitzerland
Employee Range4
Year Founded2022
Last FundingMay 5, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?